Phase 2 Study of Liposomal Irinotecan with Apatinib for Treating Extensive Stage Small Cell Lung Cancer After First-Line Treatment Progression

What this Trial Is About

This research aims to assess the effectiveness and safety of combining liposomal irinotecan with apatinib in treating extensive stage small cell lung cancer SCLC that has progressed after first-line treatment. Extensive stage SCLC is a highly aggressive cancer with rapid growth, and while initial treatments like etoposide with platinum and immunotherapy are often effective, many patients experience disease progression. Current second-line treatments offer limited success, making new combination therapies important to explore. Participants will receive a combination of liposomal irinotecan, a chemotherapy drug designed to improve stability and target tumors effectively, and apatinib, a drug that blocks blood vessel growth to tumors. This combination is being studied because it may work together to better fight the cancer. The study evaluates this treatment in patients who have failed first-line or second-line therapies, focusing on the safety and anti-tumor effects of the combined drugs. During the study, participants will be monitored for progression-free survival at six months as the primary outcome. Additional measures include response rates, progression-free survival duration, and overall survival. Assessments will include imaging to measure tumors, safety evaluations, and ongoing monitoring throughout treatment and follow-up. The trial lasts until the end of life or specified time points to gather comprehensive data on treatment impact and safety.

Liposomal Irinotecan and Apatinib in ES-SCLC